GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of 8 months in and orforglipron is still the thing I get wrong — 23 comments in the full submission. View in context.
376
c/orforglipron·submitted 5 months ago by u/canada_coverage

8 months in and orforglipron is still the thing I get wrong

Discussionbranch of 7 comments

8 months in and orforglipron is still the thing I get wrong, logged the same way every week so the comparison is at least internally fair. The relevant figures are 8 months, and they come from the same log I have kept the whole time. It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a…

Read the full submission and all 23 comments →

This branch

7 comments, started 5 months ago
u/cato_batista18 points·5 months ago

the manufacturing story is genuinely different from the injectables

replysharereportpermalink
u/farid_kuipers10 points·5 months ago·edited

the manufacturing story is genuinely different from the injectables

Agreed, and it is why the oral peptide comparison keeps misleading people.

replysharereportpermalink
u/adaeze_cabrera4 points·5 months ago

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

replysharereportpermalink
u/canada_coverageOP2 points·5 months ago

What did the tolerability table look like at that dose?

replysharereportpermalink
load more comments (1) →
u/neha_rahimi4 points·5 months ago

daily dosing changes adherence in both directions

replysharereportpermalink
u/pancreatitis_scare3 points·5 months ago

Is that from the publication or the press release?

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →